AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NBP · NASDAQ · Biotechnology

NovaBridge Biosciences (ADR) (NBP)

Develops asset-focused oncology and retinal-disease programs through dedicated therapeutic subsidiaries.

$1.79

Pre-market+0.01 (+0.56%)

At close$1.78(+2.89%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY23Mar 2023	Q2 FY23Jun 2023	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025
Revenue	10	10	4	238	0	72	0	0	0	0	0	0
Gross profit	10	10	4	238	0	72	0	0	0	0	0	0
	411	411	361	413	91	196	12	98	5	7	9	10
Research & development	223	223	182	101	39	109	4	44	1	3	3	8
	122	122	104	312	52	87	8	54	4	4	6	2
General & administrative	122	122	104	312	52	87	8	54	4	4	6	2
Operating income	−336	−336	−282	−175	−91	−125	−12	−98	−5	−7	−9	−10
	−51	−51	17	−556	21	66	−8	3	2	2	2	0
Interest income	15	15	10	2	5	2	2	2	2	2	2	0
Other non-operating income	0	−324	−81	0	0	0	0	0	0	0	0	0
Income before tax	−386	−386	−346	−731	−70	−58	−20	−95	−3	−6	−7	−10
Income tax expense	0	0	0	−384	0	7	0	−84	0	0	0	0
Net income from continuing operations	−386	−28	−346	−346	−70	−65	−20	−11	−3	−6	−7	−10
Discontinued operations	0	0	0	0	91	32	0	2	0	0	0	0
Other adjustments	0	−34	0	0	0	0	0	0	0	0	0	6
Net income	−386	−386	−346	−346	21	−33	−20	−9	−3	−6	−7	−4
EPS, basic	−$4.65	−$4.65	−$4.16	−$4.16	$0.25	−$3.50	−$0.25	−$0.11	−$0.28	−$0.07	−$0.16	−$0.09
EPS, diluted	−$4.65	−$4.65	−$4.16	−$4.16	$0.25	−$3.50	−$0.25	−$0.11	−$0.28	−$0.07	−$0.16	−$0.09
Weighted average shares, basic	83	83	83	83	81	81	81	81	82	82	44	50
Weighted average shares, diluted	83	83	83	83	81	81	81	81	82	82	44	50
EBITDA	−51	324	−276	−169	−85	−119	−6	−97	−5	−7	−9	−10
Depreciation & amortization	336	336	6	6	6	6	6	0	0	0	0	0
EBIT	−336	−12	−282	−175	−91	−125	−12	−98	−5	−7	−9	−10